Skip to content

Total debt at other companies

Exelixis logo
ExelixisEXEL
$169.54M-9.4%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$350.49M+4.2%
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
$834K-27.7%
Johnson & Johnson logo
Johnson & JohnsonJNJ
Amgen logo
AmgenAMGN
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Revenue$18.3M+29.5%
Gross profit$18.0M
Operating income-$78.8M-21.8%
Net income-$73.3M-27.7%
EPS (diluted)-$0.83-25.8%

Balance sheet

See full
Cash & equivalents$39.1M-23.8%
Total equity$107.9M-70.4%
Total assets$652.6M-12.3%

Cash flow

See full
Operating cash flow-$85.9M-19.4%
CapEx$128.0K-56.2%
Free cash flow-$86.0M-19.1%

Valuation

See full
Market cap$942.78M+86.2%
Enterprise value$927.97M+95.5%
P/S13.2×+3.9×

Profitability

See full
Operating margin-443.5%+103pp
Net margin-411.2%+125pp
FCF margin130.6%+74.1pp

Returns & leverage

See full
Return on equity-124.7%-252pp
Debt / equity0.2×+0.2×
Current ratio6.1×-1.9×

Where this comes from

Calculated from Kura Oncology’s reported figures.

Plus components not separately reported this period.

The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kura Oncology's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kura Oncology's total debt?
Kura Oncology (KURA) reported total debt of $24.27M in Q1 2026.
How has Kura Oncology's total debt changed year-over-year?
Kura Oncology's total debt increased by 25.4% year-over-year, from $19.35M to $24.27M.
What is the long-term trend for Kura Oncology's total debt?
Over 5 years (2020 to 2025), Kura Oncology's total debt has grown at a 6.5% compound annual growth rate (CAGR), from $14.95M to $20.46M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.